Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases.
Glück
T
T
Linde
H-J
HJ
Schölmerich
J
J
Müller-Ladner
U
U
Fiehn
C
C
Bohland
P
P
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D002764:Cholecystitis / Q000209:etiology / Q000473:pathology; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000276:immunology*; D000069285:Infliximab; D008089:Listeria monocytogenes / Q000302:isolation & purification* / Q000472:pathogenicity; D008088:Listeriosis / Q000139:chemically induced* / Q000473:pathology; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D000069285:Infliximab